Catalog Number : 500-P10G
Produced from sera of goats pre-immunized with highly pure (>98%) recombinant hVEGF. Anti-Human VEGF specific antibody was purified by affinity chromatography employing immobilized hVEGF matrix.
|Application:||ELISA, Western Blot, Neutralization, Immunohistochemistry|
Anti-Human VEGF (BioGems Catalog #100-20)
This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentrations are 5.0 µg/ml-15.0 µg/ml with a 30-minute incubation at room temperature or an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with a DAB chromogen. This antibody was also tested in an HRP-biotin labeling detection system. Heat induced antigen retrieval with a pH 6.0 Sodium Citrate buffer is recommended. Optimal concentrations and conditions may vary.
To yield one-half maximal inhibition [ND50] of the biological activity of hVEGF (10 ng/ml), a concentration of 0.05 - 0.1 µg/ml of this antibody is required.
To detect hVEGF by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems' Biotinylated Anti-Human VEGF (60-342GBT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hVEGF.
To detect hVEGF by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hVEGF is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.